Nkarta, Inc. Operating Lease Right-of-Use Assets
Nkarta, Inc. (NKTX) had Operating Lease Right-of-Use Assets of $30.94 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-10
- 2026-06-30: Operating Lease, Right-of-Use Asset $30.94M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $33.88M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $34.43M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $33.80M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $30.94M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $33.88M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $34.43M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $33.80M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $35.08M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $35.53M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $36.01M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $38.80M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $39.37M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $39.36M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $39.95M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $40.52M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $41.07M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $45.58M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $45.75M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $67.97M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $66.03M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $65.47M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $11.68M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $12.07M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $12.05M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $11.87M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $8.51M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $8.76M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $9.02M 10-Q · filed 2020-08-20 | |
| 2019-12-31 | $7.14M 10-K · filed 2021-03-25 | $7.14M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |